Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib : ENESTcmr 12-month (mo) follow-up

Autoria(s): Lipton, Jeffrey Howard; Hughes, Timothy P.; Leber, Brian; De Souza, Carmino; Dorlhiac-Llacer, Pedro E.; Steegmann, Juan Luis; Guerci-Bresler, Agnes; Schwarer, Anthony P.; Cervantes, Francisco; Reynolds, John; Collins, LaTonya R.; Szczudlo, Tomasz K.; Spector, Nelson
Data(s)

20/05/2012
Identificador

http://hdl.handle.net/10536/DRO/DU:30060094
Idioma(s)

eng
Publicador

American Society of Clinical Oncology
Relação

http://dro.deakin.edu.au/eserv/DU:30060094/reynolds-switchtonilotinib-2012.pdf

http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/6505?sid=cbd5f08a-e5a0-40ff-9420-4601ed43f921
Palavras-Chave #nilotinib #imatinib #patients #chronic myeloid leukemia in chronic phase (CML-CP)
Tipo

Journal Article
Acesso ao item digital